Supplementary Table 14. Performance metrics for Biochemical recurrence (Glinsky) and Metastatic recurrence (Erho) for the Metastatic Assay Metric Metastatic Assay Metastatic (Glinsky cohort) (Erho cohort) 70.27% [56.41-80.00] 66.67% [52.44-76.63] Sensitivity 66.98% [60.51-71.36] 54.65% [50.43-57.38] Specificity Supplementary Table 15. Performance metrics for metastatic recurrence for CAPRA-S and the Combined Model (CAPRA-S + Metastatic Assay) Metric Metastatic Assay CAPRA-S Combined Model 47.73% [32.46-63.31] 70.45% [54.80-83.24] 84.09% [69.93-93.36] Sensitivity 81.87% [75.69-87.03] 71.50% [64.58-77.75] 64.14% [53.88-68.06] Specificity
Supplementary Table 15. Performance metrics for metastatic recurrence for CAPRA-S and the Combined Model (CAPRA-S + Metastatic Assay) Metric Metastatic Assay CAPRA-S Combined Model Sensitivity 47.73% [32.46-63.31] 70.45% [54.80-83.24] 84.09% [69.93-93.36] Specificity 81.87% [75.69-87.03] 71.50% [64.58-77.75] 64.14% [53.88-68.06] Supplementary Table 14. Performance metrics for Biochemical recurrence (Glinsky) and Metastatic recurrence (Erho) for the Metastatic Assay Metric Metastatic Assay (Glinsky cohort) Metastatic (Erho cohort) Sensitivity 70.27% [56.41-80.00] 66.67% [52.44-76.63] Specificity 66.98% [60.51-71.36] 54.65% [50.43-57.38]
REF%20EURUROL-D-16-01757%202nd%20Re-submission%20%28MARK-UP%29.docx